Timothy Grass Pollen Therapeutic Vaccine: Optimal Dose for Subcutaneous Immunotherapy

Sola, Javier; Ferreira, José Alberto; Elera, Javier Dionicio; Plácido, José Luís; Pereira, Celso; Fonseca, João; Panizo, C; Inácio, Luís Filipe; Cancelleire, Nataly; Zubeldía, J M; Landeta, Araitz; Madariaga, Begoña; Martı́nez, Alberto

doi:10.2217/imt.15.125

Immunotherapy

2016

DOI: 10.2217/imt.15.125

|View full text |Cite|

Timothy Grass Pollen Therapeutic Vaccine: Optimal Dose for Subcutaneous Immunotherapy

Javier Sola

José Alberto Ferreira

Javier Dionicio Elera

et al.

Abstract: P. pratense depot SCIT showed signs of clinical and immunological efficacy by dose-dependently decreasing the allergen sensitization rate. Risk-benefit favored doses below 1.0 SPT units for confirmatory trials.

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...

Citation Types

Supporting

Mentioning

Contrasting

Year Published

2018

2024

Publication Types

Select...

Article6

Relationship

Self Cite0

Independent6

Authors

Journals

Cited by 6 publications

(1 citation statement)

References 35 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Designing allergen composition and monitoring the clinical efficacy of immunotherapy for patients with allergic rhinitis. 739,[951][952][953] 4. Determining clinical relevance of a specific allergen in patients of allergic rhinitis with multiple positive allergy skin tests.…”

mentioning

confidence: 99%

Indian Guidelines for Diagnosis of Respiratory Allergy

Prasad¹,

Prakash²,

Kumar³

et al. 2022

The Indian Journal of Chest Diseases and Allied Sciences

View full text Add to dashboard Cite

mentioning

confidence: 99%

Indian Guidelines for Diagnosis of Respiratory Allergy

Prasad¹,

Prakash²,

Kumar³

et al. 2022

The Indian Journal of Chest Diseases and Allied Sciences

View full text Add to dashboard Cite

Systemic Allergic Reactions and Anaphylaxis Associated with Allergen Immunotherapy

Dhamija

Epstein

Bernstein

2022

Immunology and Allergy Clinics of North America

View full text Add to dashboard Cite

EAACI Position paper on the standardization of nasal allergen challenges

Augé

Vent

Agache

et al. 2018

Allergy

203

262

View full text Add to dashboard Cite

Nasal allergen challenge (NAC) is an important tool to diagnose allergic rhinitis. In daily clinical routine, experimentally, or when measuring therapeutic success clinically, nasal allergen challenge is fundamental. It is further one of the key diagnostic tools when initiating specific allergen immunotherapy. So far, national recommendations offered guidance on its execution; however, international divergence left many questions unanswered. These differences in the literature caused EAACI to initiate a task force to answer unmet needs and find a consensus in executing nasal allergen challenge. On the basis of a systematic review containing nasal allergen challenges of the past years, task force members reviewed evidence, discussed open issues, and studied variations of several subjective and objective assessment parameters to propose a standardized way of a nasal allergen challenge procedure in clinical practice. Besides an update on indications, contraindications, and preparations for the test procedure, main recommendations are a bilaterally challenge with standardized allergens, with a spray device offering 0.1 mL per nostril. A systematic catalogue for positivity criteria is given for the variety of established subjective and objective assessment methods as well as a schedule for the challenge procedure. The task force recommends a unified protocol for NAC for daily clinical practice, aiming at eliminating the previous difficulty of comparing NAC results due to unmet needs.

show abstract

scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.

Contact Info

customersupport@researchsolutions.com

10624 S. Eastern Ave., Ste. A-614

Henderson, NV 89052, USA

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Blog Terms and Conditions API Terms Privacy Policy Contact Cookie Preferences Do Not Sell or Share My Personal Information

Made with 💙 for researchers

Part of the Research Solutions Family.

Timothy Grass Pollen Therapeutic Vaccine: Optimal Dose for Subcutaneous Immunotherapy

Abstract: P. pratense depot SCIT showed signs of clinical and immunological efficacy by dose-dependently decreasing the allergen sensitization rate. Risk-benefit favored doses below 1.0 SPT units for confirmatory trials.

Cited by 6 publications

References 35 publications

Indian Guidelines for Diagnosis of Respiratory Allergy

Indian Guidelines for Diagnosis of Respiratory Allergy

Systemic Allergic Reactions and Anaphylaxis Associated with Allergen Immunotherapy

EAACI Position paper on the standardization of nasal allergen challenges

Contact Info

Product

Resources

About